Lipid spectrum changes and ECG in patients with paranoid schizophrenia in the course of therapy with atypical antipsychotics

Smirnova, L.; Parshukova, D.; Borodyuk, Y N; Kornetova, E.; Tkacheva, G D; Seregin, A.; Burdovitsina, T G; Semke, A.

doi:10.17116/jnevro20151153149-53

Cited by 4 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Психопатология, клиническая и биологическая психиатрия Психиатрия 18(2)'2020'32-38 МИА' ISSN1683-8319 (print)' journalpsychiatry.com DOI 10.30629/2618DOI 10.30629/ -6667-2020 из группы антипсихотиков, что неотъемлемо связано с развитием ряда нежелательных явлений [4]. Одним из самых распространенных двигательных побочных нарушений у больных шизофренией в психиатрической практике является акатизия.…”

unclassified

“…Акатизия затрагивает не только клинико-динамические аспекты шизофренического процесса, но и поведенческие паттерны пациентов [5]. Частота ее встречаемости у больных шизофренией на фоне терапии антипсихотиками варьирует в достаточно широком диапазоне: от 8% до 76% [4], что связывают с использованием конкретных препаратов и их фармакологическим профилем. Проводимые исследования демонстрируют, что применение КАП повышает риск развития акатизии в сравнении с ААП [6], что находит свое отражение в высокой частоте ее встречаемости на фоне приема галоперидола, который выступает по-прежнему эталонным препаратом в терапии больных шизофренией и достигает 57-75% [7].…”

unclassified

See 1 more Smart Citation

The Role of Antypsychotic Therapy in the Development of Akathisia in Patients with Schizophrenia

Goncharova

Kornetova

2020

Psychiatry

Self Cite

View full text Add to dashboard Cite

The use of antipsychotic therapy in patients with schizophrenia is associated with the development of a wide range of adverse events, among which akathisia is one of the most common. Objective: to assess the risk of akathisia in patients with schizophrenia receiving various antipsychotic therapy. Patients and methods. A continuous method examined 250 inpatients with a verified diagnosis of schizophrenia. The akathisia assessment was performed using the Barnes Akathisia Rating Scale (BARS). The odds ratio was estimated using the MedCalc® online calculator. Results: akathisia was detected in 92 (36.8%) examined. The combination of two antipsychotic drugs has an increased risk of akathisia in patients with schizophrenia OR = 1.69 (95% CI: 1.0–2.88; p = 0.04), however the use of conventional and atypical drugs was associated with a reduction in risk (OR = 0.45 (95% CI: 0.21–0.95; p = 0.037)). Patients receiving basic therapy zuclopenthixol decanoate had increased risk of akathisia 4 times as compared to haloperidol decanoate (OR = 3.85 (95% CI: 1,26–12,22; p = 0.021)). Conclusions: It was shown that the choice of antipsychotic therapy should be based not only on the actual mental state of the patient, but also considering the potential risk of akathisia.

show abstract

unclassified

The Role of Antypsychotic Therapy in the Development of Akathisia in Patients with Schizophrenia

Goncharova

Kornetova

2020

Psychiatry

Self Cite

View full text Add to dashboard Cite

show abstract

Risperidone and Cardiometabolic Risk in Children and Adolescents

Matera¹,

Margari²,

Palmieri³

et al. 2017

J Clin Psychopharmacol

View full text Add to dashboard Cite

In our sample, several metabolic parameters showed a sensitivity to risperidone treatment. Because most of these parameters are age dependent, metabolic syndrome criteria used for adults were inappropriate in children and adolescents. Periodic clinical and instrumental evaluations and guidelines for monitoring of any metabolic, laboratory, and instrumental complications are necessary in the perspective of even long-time second-generation antipsychotics treatment in children and adolescents.

show abstract

Safety of pharmacotherapy in a psychiatric inpatient setting and the QT interval

Kirilochev

Олегович²

2021

Annals RAMS

View full text Add to dashboard Cite

Background; Events associated with a risk of death are the most serious complications of pharmacotherapy; One of these complications is prolongation of the QT interval leading to Torsades de Pointes, a life-threatening condition that can result in asystole and sudden death. Factors contributing to the development of the long QT syndrome include heredity, structural abnormalities of the heart, electrolyte disorders, female gender, advanced age, use of drugs with certain electrophysiological properties, and drug-drug interactions. Consideration of all these factors can help achieve the most accurate and objective assessment of the risk of these rhythm disturbances. Aims to assess the risk of prolongation of the QT interval and the development of Torsades de Pointes in psychiatric inpatients. Methods. The study enrolled 500 patients who received medical care in a psychiatric inpatient setting. The risk of QT interval prolongation and development of Torsades de Pointes was assessed using the MedSafety Scan medical decision support system. Results. Of the 500 patients treated in the psychiatric inpatient setting, 224 had a risk of QT interval prolongation and developing Torsades de Pointes; the incidence was highest in the group of elderly patients. The mean risk score was 7.59 3.29 in general, 6.02 3.14 in patients aged under 65 years, and 9.16 2.62 in subjects over 65 years of age. An analysis of the frequencies of risk factors for prolongation of the QT interval and Torsades de Pointes revealed that patients aged over 65 years most commonly had atrial fibrillation, chronic heart failure, heart valve disorders, hypertension, and a history of myocardial infarction. Patients under 65 years of age more commonly received medicinal products prolonging the QT interval and drug combinations that can lead to potential drug-drug interactions of relevant clinical significance. Conclusion. The obtained results indicate the importance of assessing the risk of QT interval prolongation and development of Torsades de Pointes in psychiatric inpatients as an affordable preventive tool that can increase the safety of drug therapy.

show abstract

Lipid spectrum changes and ECG in patients with paranoid schizophrenia in the course of therapy with atypical antipsychotics

Cited by 4 publications

References 6 publications

The Role of Antypsychotic Therapy in the Development of Akathisia in Patients with Schizophrenia

The Role of Antypsychotic Therapy in the Development of Akathisia in Patients with Schizophrenia

Risperidone and Cardiometabolic Risk in Children and Adolescents

Safety of pharmacotherapy in a psychiatric inpatient setting and the QT interval

Contact Info

Product

Resources

About